Jaul-Paul Prieels

Jaul-Paul Prieels holds a PhD in Biochemistry from Université Libre de Bruxelles in Belgium. After ten years at university, he started his industrial career at Petrofina in 1983 as Biotechnology Manager and joined GlaxoSmithKline Biologicals in 1987. His responsibilities gradually expanded to lead the vaccine preclinical R&D development activities in Rixensart, Belgium, and he retired as Senior Vice President of Research & Development in 2011. He was instrumental in the development of several commercially available vaccines, such as Rotarix, Cervarix and Synflorix. Today, he is Director at various companies and member of the Scientific Advisory Board of Singapore Bioprocessing Technology Institute and MolMed SPA. He is also a member of the European Vaccine Initiative Board of Stakeholders.